Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers

Overview

Journal Biologics

Date 2021 Nov 10

PMID 34754178

Citations 4

Authors

Mimma Rizzo

Patrizia Giannatempo

Camillo Porta

Affiliations

Soon will be listed here.

Abstract

In recent years, diagnostic and therapeutic advances have contributed to a reduction in mortality rates of patients with metastatic urothelial carcinoma (mUC). Immune checkpoint inhibitors have demonstrated efficacy and safety as both first-line and first-line switch maintenance therapy for mUC. For platinum-refractory patients, in addition to immunotherapy, other targeted agents (antibody-drug conjugates and fibroblast growth factor receptor inhibitors) have been approved after demonstrating a clinically relevant advantage in overall response rate, progression-free survival, and overall survival compared to standard of care. Sequential treatment strategies are finally feasible for patients with advanced urothelial carcinoma. This review will summarize the results of the most important phase II-III clinical trials for first-line, switch maintenance, second-line, and subsequent lines of therapy, and describe the most promising clinical trials currently ongoing in these treatment scenarios.

Citing Articles

Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.

Pezzicoli G, Ciciriello F, Musci V, Minei S, Biasi A, Ragno A Medicina (Kaunas). 2024; 60(4).

PMID: 38674231 PMC: 11052409. DOI: 10.3390/medicina60040585.

Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study.

Pezzicoli G, Salonne F, Musci V, Ciciriello F, Tommasi S, Lacalamita R J Clin Med. 2023; 12(24).

PMID: 38137830 PMC: 10744017. DOI: 10.3390/jcm12247761.

Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer.

Sevim Nalkiran H, Akcora Yildiz D, Saydam F, Guzel A, Nalkiran I Saudi J Biol Sci. 2023; 30(3):103564.

PMID: 36794046 PMC: 9923226. DOI: 10.1016/j.sjbs.2023.103564.

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.

Zhang X, Li H, Lv X, Hu L, Li W, Zi M Life (Basel). 2022; 12(3).

PMID: 35330159 PMC: 8951256. DOI: 10.3390/life12030409.

References

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2005; 42(1):50-4. DOI: 10.1016/j.ejca.2005.08.032. View

Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E . Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019; 381(4):338-348. DOI: 10.1056/NEJMoa1817323. View

Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M . Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(3):329-354. DOI: 10.6004/jnccn.2020.0011. View

De Santis M, Bellmunt J, Mead G, Kerst J, Leahy M, Maroto P . Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009; 27(33):5634-9. PMC: 2792956. DOI: 10.1200/JCO.2008.21.4924. View

Novakovic A, Wilkins J, Dai H, Wade J, Neuteboom B, Brar S . Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Clin Pharmacol Ther. 2019; 107(3):588-596. PMC: 7027979. DOI: 10.1002/cpt.1645. View

Necchi A, Lo Vullo S, Raggi D, Gloghini A, Giannatempo P, Colecchia M . Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort. Eur Urol Focus. 2018; 5(5):853-856. DOI: 10.1016/j.euf.2018.02.013. View

Sternberg C, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F . Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019; 76(1):73-81. DOI: 10.1016/j.eururo.2019.03.015. View

10.

Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W . Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011; 29(17):2432-8. DOI: 10.1200/JCO.2011.34.8433. View

11.

Rosenberg J, Ballman K, Halabi S, Atherton P, Mortazavi A, Sweeney C . Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021; 39(22):2486-2496. PMC: 8462587. DOI: 10.1200/JCO.21.00286. View

12.

Bellmunt J, von der Maase H, Mead G, Skoneczna I, De Santis M, Daugaard G . Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30(10):1107-13. PMC: 3341152. DOI: 10.1200/JCO.2011.38.6979. View

13.

Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G . Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016; 14(1):282. PMC: 5041438. DOI: 10.1186/s12967-016-1037-z. View

14.

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Powles T, Rosenberg J, Sonpavde G, Loriot Y, Duran I, Lee J . Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 384(12):1125-1135. PMC: 8450892. DOI: 10.1056/NEJMoa2035807. View

17.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

18.

Feld E, Harton J, Meropol N, Adamson B, Cohen A, Parikh R . Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. Eur Urol. 2019; 76(4):524-532. PMC: 6822167. DOI: 10.1016/j.eururo.2019.07.032. View

19.

Bellmunt J, Orsola A, Leow J, Wiegel T, De Santis M, Horwich A . Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii40-8. DOI: 10.1093/annonc/mdu223. View

20.

Balar A, Castellano D, ODonnell P, Grivas P, Vuky J, Powles T . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11):1483-1492. DOI: 10.1016/S1470-2045(17)30616-2. View